Weight-Loss Drugs May Slow Aging, Drugmakers Say

Drugmakers Eli Lilly and Novo Nordisk have announced that their popular GLP-1 weight-loss drugs may do more than help people shed pounds — they might also slow the aging process. The companies used molecular 'aging clocks' that track changes in DNA or key proteins to measure how quickly patients' bodies are aging. Early results suggest patients on these drugs age more slowly at the cellular level. This adds to excitement that GLP-1 drugs could be true longevity treatments, not just weight-loss tools.

But how much can we really read into these results? The findings are preliminary and haven't been fully peer-reviewed. Aging is complex, and slowing it in a lab test doesn't always mean living longer or healthier. Still, the news is significant because it hints that these drugs might target basic causes of aging — not just appetite. If confirmed, that could mean fewer age-related diseases like heart disease, dementia, and frailty.

For everyday people, this matters because millions already take these drugs for weight loss or diabetes. If they also slow aging, the benefits could be huge: more healthy years, lower healthcare costs, and better quality of life. But the drugs are expensive, can have side effects, and are not yet approved for anti-aging. Experts say don't rush to get a prescription just for longevity — more research is needed.

In other tech news, a company called Energy Dome is building giant batteries that store renewable energy using compressed carbon dioxide. Unlike older compressed-air systems, theirs doesn't need special underground caves, so it can be built almost anywhere. That could help make solar and wind power more reliable. Also, a former DeepMind researcher warns that today's AI doesn't truly reason — a reminder that not all tech breakthroughs are what they seem.